Spondyloarthritides: Theories and beyond
Spondyloarthritides (SpA) are a family of interrelated rheumatic disorders with a typical disease onset ranging from childhood to middle age. If left untreated, they lead to a severe decrease in patients' quality of life. A succesfull treatment strategy starts with an accurate diagnosis which i...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-12-01
|
| Series: | Frontiers in Pediatrics |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fped.2022.1074239/full |
| _version_ | 1797978679765106688 |
|---|---|
| author | Begüm Kocatürk Zeynep Balık Gaye Pişiren Umut Kalyoncu Füsun Özmen Seza Özen |
| author_facet | Begüm Kocatürk Zeynep Balık Gaye Pişiren Umut Kalyoncu Füsun Özmen Seza Özen |
| author_sort | Begüm Kocatürk |
| collection | DOAJ |
| description | Spondyloarthritides (SpA) are a family of interrelated rheumatic disorders with a typical disease onset ranging from childhood to middle age. If left untreated, they lead to a severe decrease in patients' quality of life. A succesfull treatment strategy starts with an accurate diagnosis which is achieved through careful analysis of medical symptoms. Classification criterias are used to this process and are updated on a regular basis. Although there is a lack of definite knowledge on the disease etiology of SpA, several studies have paved the way for understanding plausible risk factors and developing treatment strategies. The significant increase of HLA-B27 positivity in SpA patients makes it a strong candidate as a predisposing factor and several theories have been proposed to explain HLA-B27 driven disease progression. However, the presence of HLA-B27 negative patients underlines the presence of additional risk factors. The current treatment options for SpAs are Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), TNF inhibitors (TNFis), Disease-Modifying Anti-Rheumatic Drugs (DMARDs) and physiotherapy yet there are ongoing clinical trials. Anti IL17 drugs and targeted synthetic DMARDs such as JAK inhibitors are also emerging as treatment alternatives. This review discusses the current diagnosis criteria, treatment options and gives an overview of the previous findings and theories to clarify the possible contributors to SpA pathogenesis with a focus on Ankylosing Spondylitis (AS) and enthesitis-related arthritis (ERA). |
| first_indexed | 2024-04-11T05:26:51Z |
| format | Article |
| id | doaj.art-225dea61c535458e829a7ee435002871 |
| institution | Directory Open Access Journal |
| issn | 2296-2360 |
| language | English |
| last_indexed | 2024-04-11T05:26:51Z |
| publishDate | 2022-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pediatrics |
| spelling | doaj.art-225dea61c535458e829a7ee4350028712022-12-23T05:24:16ZengFrontiers Media S.A.Frontiers in Pediatrics2296-23602022-12-011010.3389/fped.2022.10742391074239Spondyloarthritides: Theories and beyondBegüm Kocatürk0Zeynep Balık1Gaye Pişiren2Umut Kalyoncu3Füsun Özmen4Seza Özen5Department of Basic Oncology, Hacettepe University Cancer Institute, Ankara, TurkeyDivision of Pediatric Rheumatology, Department of Pediatrics, Hacettepe University Faculty of Medicine, Ankara, TurkeyDepartment of Basic Oncology, Hacettepe University Cancer Institute, Ankara, TurkeyDivision of Rheumatology, Department of Internal Medicine, Hacettepe University Faculty of Medicine, Ankara, TurkeyDepartment of Basic Oncology, Hacettepe University Cancer Institute, Ankara, TurkeyDivision of Pediatric Rheumatology, Department of Pediatrics, Hacettepe University Faculty of Medicine, Ankara, TurkeySpondyloarthritides (SpA) are a family of interrelated rheumatic disorders with a typical disease onset ranging from childhood to middle age. If left untreated, they lead to a severe decrease in patients' quality of life. A succesfull treatment strategy starts with an accurate diagnosis which is achieved through careful analysis of medical symptoms. Classification criterias are used to this process and are updated on a regular basis. Although there is a lack of definite knowledge on the disease etiology of SpA, several studies have paved the way for understanding plausible risk factors and developing treatment strategies. The significant increase of HLA-B27 positivity in SpA patients makes it a strong candidate as a predisposing factor and several theories have been proposed to explain HLA-B27 driven disease progression. However, the presence of HLA-B27 negative patients underlines the presence of additional risk factors. The current treatment options for SpAs are Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), TNF inhibitors (TNFis), Disease-Modifying Anti-Rheumatic Drugs (DMARDs) and physiotherapy yet there are ongoing clinical trials. Anti IL17 drugs and targeted synthetic DMARDs such as JAK inhibitors are also emerging as treatment alternatives. This review discusses the current diagnosis criteria, treatment options and gives an overview of the previous findings and theories to clarify the possible contributors to SpA pathogenesis with a focus on Ankylosing Spondylitis (AS) and enthesitis-related arthritis (ERA).https://www.frontiersin.org/articles/10.3389/fped.2022.1074239/fullmedical biologyspondyloarthritidesankylosing spondylitisenthesitis-related arthritisrheumatology |
| spellingShingle | Begüm Kocatürk Zeynep Balık Gaye Pişiren Umut Kalyoncu Füsun Özmen Seza Özen Spondyloarthritides: Theories and beyond Frontiers in Pediatrics medical biology spondyloarthritides ankylosing spondylitis enthesitis-related arthritis rheumatology |
| title | Spondyloarthritides: Theories and beyond |
| title_full | Spondyloarthritides: Theories and beyond |
| title_fullStr | Spondyloarthritides: Theories and beyond |
| title_full_unstemmed | Spondyloarthritides: Theories and beyond |
| title_short | Spondyloarthritides: Theories and beyond |
| title_sort | spondyloarthritides theories and beyond |
| topic | medical biology spondyloarthritides ankylosing spondylitis enthesitis-related arthritis rheumatology |
| url | https://www.frontiersin.org/articles/10.3389/fped.2022.1074239/full |
| work_keys_str_mv | AT begumkocaturk spondyloarthritidestheoriesandbeyond AT zeynepbalık spondyloarthritidestheoriesandbeyond AT gayepisiren spondyloarthritidestheoriesandbeyond AT umutkalyoncu spondyloarthritidestheoriesandbeyond AT fusunozmen spondyloarthritidestheoriesandbeyond AT sezaozen spondyloarthritidestheoriesandbeyond |